Gene synthesis, cloning, plasmid preparation and expressions and purification. DNA constructs must be delivered in an indexed 96-w

This is a Notice of Intent to award, not a request for Quotation. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genscript USA Incorporated for Gene Synthesis. The efforts and analyses require DNA synthesis of antibody sequences, downstream cloning into expression vectors, plasmid preparation and antibody expression and purification. An additional requirement for this project is to provide the DNA constructs must be delivered in an indexed 96-well format

Description of services:

GenPlus Next-Gen Gene Synthesis  QTY:2000 
GenPlus cloning: Heavy Chain Target VectorArk Vector: VRC specified vector Cloning method

GenPlus Next-Gen Gene Synthesis: QTY:2000
           GenPlus cloning:Light Chain Target VectorArk Vector:VRC specified vector Cloning 
           method: VRC specified method Delivery
           Also to provide the DNA constructs must be delivered in an indexed 96-well format

GenScript focuses exclusively on early drug discovery and development services, it offers molecular biology services ranging from gene synthesis and custom cloning, to advanced genetic engineering and mutant libraries. With in‐house oligo synthesis capability and well‐equipped molecular biology laboratory, this company provides reliable and flexible molecular biology service solutions that cover almost all aspects in discovery research. This company also stores synthesized plasmids that we ordered before so that we can conveniently clone genes needed for our previous DNA plasmids. This request will include DNA synthesis, cloning, plasmid preparation and antibody expression and purification. To also provide the DNA constructs to be delivered in an indexed 96-well format. This service needs to also provide VectorArk/CloneArk System for NIH to archive, share and reuse their vectors and archived clones.

The results from these services will be used at NIH for continued COVID19 studies within the Vaccine Research Center in Bethesda, MD

The Place of performance NIH, VACCINE RESEARCH CENTER 40 CONVENT DR BETHESDA, MD 20814

The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106‐1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR
QUOTES.  Due to the  nature of this requirement, COVID19, and the urgency to develop a vaccine, the posting deadline has been shortened to five days.  All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI‐RML‐C‐2032033 to Diana Rohlman at diana.rohlman@nih.gov by 9:00 AM Mountain Standard Time, August 4, 2020. All compatibility responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.